<DOC>
	<DOCNO>NCT02739594</DOCNO>
	<brief_summary>This multicenter , open-label trial randomize participant multiple myeloma regimen ibandronate zoledronate order compare incidence nephrotoxicity , measure creatinine clearance ( CrCl ) reduction great ( &gt; ) 30 percent ( % ) absolute value 30 milliliter per minute ( mL/min ) low .</brief_summary>
	<brief_title>Comparison Ibandronate - Zoledronate Regarding Nephrotoxicity Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Confirmed multiple myeloma , Stage IIIII per Salmon Durie ( 1975 ) Indication biphosphonate therapy Previous therapy ibandronate zoledronate within past 12 month Renal insufficiency serum creatinine &gt; 3.0 mg/dL &gt; 265 micromoles per liter ( µmol/L ) CrCl &lt; 30 mL/min Hypersensitivity ibandronate , zoledronate , biphosphonates Presence secondary malignomas , apart basaliomas cervical carcinoma situ Severe accompany illness organ impairment Osteonecrosis jaw start study Life expectancy ≤12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>